<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848184</url>
  </required_header>
  <id_info>
    <org_study_id>COVPCOV0293</org_study_id>
    <nct_id>NCT01848184</nct_id>
  </id_info>
  <brief_title>A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch</brief_title>
  <acronym>Panacea</acronym>
  <official_title>A Multicentre Prospective Study in Patients Undergoing Ventral Hernia Repair by Open Approach With Intraperitoneal Positioning Using Parietex™ Composite Ventral Patch - Panacea Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the recurrence rate following the use of PARIETEX™
      Composite Ventral Patch in primary ventral hernia repair by open approach with
      intra‐peritoneal positioning.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter, multinational non‐comparative study.

      Primary Endpoint: Primary hernia recurrence* rate at 24 month follow‐up. The evaluation of
      hernia recurrence will be performed during a physical examination and by ultrasonography.

      Secondary Endpoints: Primary hernia recurrence* rate at 1, 6 and 12 month follow‐up. The
      evaluation of hernia recurrence will be performed during a physical examination and confirmed
      by ultrasonography.

      (*Recurrence is defined as a clinically manifested bulge or a protrusion exacerbated by a
      Valsalva maneuver.)

      Safety Parameters:

      Deep and superficial infection (A Surgical Site Infection (SSI) will be defined in the study
      according to the Centers for Disease Control and Prevention (CDC) criteria for diagnosis of
      SSI).

      Pain / Chronic pain Other post‐operative complications (complications related to visceral
      adhesions, Ileus, seroma, hematoma...) Analgesics consumption Risk factors (severity and
      treatment) Efficacy Parameters: Recurrence of primary ventral hernia Operative time Time of
      the mesh positioning Length of Hospital Stay Ease of use (Mesh handling and manipulability,
      comfort of use …) Return to daily activities/ work Patient satisfaction Patient comfort
      (Carolina's™ Comfort scale (CCS) - QoL questionnaire)

      Visit Schedule:

      Baseline visit (Preoperative) &amp; Operative/Discharge visit

      Post-Op:

      Phone call Day 10

      1 month 6 months 12 months 24 months

      Duration: 12 months recruitment and 24 months follow‐up Up to 12 sites in Europe and the
      United States will be included in this study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Hernia Recurrence Rate at 24 Month Follow‐up.</measure>
    <time_frame>24 month follow‐up</time_frame>
    <description>The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rate at 1, 6 and 12 Month Follow‐up</measure>
    <time_frame>1, 6 and 12 month follow‐up.</time_frame>
    <description>The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Score at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months</measure>
    <time_frame>Various (Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months)</time_frame>
    <description>Pain evaluation as determined by a 10-point pain intensity numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain). Scores reported at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months</description>
  </other_outcome>
  <other_outcome>
    <measure>Summary of Risk Factors at Baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Summary of Risk factors at Baseline. Risk factors include: Smoker, Obesity, Diabetes T1 &amp; T2, Cancer, Cardiovascular disease, Hypertension, COPD, Chronic desease requiring analgesic or corticoid consumption</description>
  </other_outcome>
  <other_outcome>
    <measure>Mesh Handling Ease of Use During Surgery</measure>
    <time_frame>Per- operative</time_frame>
    <description>Ease of use (mesh handling and comfort of use). Surgeons were asked if they were satisfied or completely satisfied, unsatisfied or completely dissatisfied</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Relevant Data: Operative Time</measure>
    <time_frame>Per- operative</time_frame>
    <description>Operative time during surgery for all patient receiving PCO ventral patch</description>
  </other_outcome>
  <other_outcome>
    <measure>Other Relevant Data: Time of Mesh Positioning</measure>
    <time_frame>Per- operative</time_frame>
    <description>The time of the mesh positioning during surgery</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">126</enrollment>
  <condition>Hernia</condition>
  <arm_group>
    <arm_group_label>PARIETEX™ Composite Ventral Patch</arm_group_label>
    <description>PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PARIETEX™ Composite Ventral Patch</intervention_name>
    <description>PARIETEX™ Composite Ventral Patch for ventral hernia repair</description>
    <arm_group_label>PARIETEX™ Composite Ventral Patch</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients eligible for a primary ventral hernia repair with mesh by open approach
        (scheduled for non-emergent elective surgery with PCO VP) will be assessed for potential
        study participation (screening) and will be recorded in the patient log.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients (adult ≥ 18 years) at participating centres undergoing primary ventral
             hernia repair with the device by open approach

          -  Signed informed consent form by the patient or the legally authorized representative

          -  Intraoperative inclusion criteria :Size of the defect: ≤ 4 cm

        Exclusion Criteria:

          -  Emergency procedure

          -  Current participation in other trials

          -  History of previous hernia at the same location.

          -  Pregnant women: Women who are known or suspected to be pregnant, or who are planning
             to become pregnant during the study follow‐up period

          -  Patient &lt; 18 years

          -  BMI &gt; 35

          -  ASA score ≥ 4

          -  The investigator determined that the patient will not be able to comply with the
             required follow‐up visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederik Berrevoet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ghent (Belgium)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars N Jørgensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, University of Copenhagen (Denmark)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl Doerhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Surgicare of MO (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Hopson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hernia Centers of Excellence, VA (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric KULLMAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicinskt Centrum i Linköping (Sweden)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco G MUZI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, University Hospital Tor Vergata, Roma (Italy)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon NIENHUIJS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis, EJ EINDHOVEN (The Netherlands)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip E Muysoms, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algemene Heelkunde, AZ Maria Middelares Ghent (Belgium)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Tollens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imelda Hospital, Bonheiden (Belgium)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Leblanc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Our Lady of the Lake Regional Medical Center, LA (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monmouth Medical Center, NJ (United States)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vic Velanovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida (United States)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>78080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgicare of Missouri</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hernia Centers of Excellence</name>
      <address>
        <city>Yorktown</city>
        <state>Virginia</state>
        <zip>23692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Surgery - Imelda Hospital</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery, Algemene Heelkunde AZ Maria Middelares Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Surgery K, Bispebjerg Hospital, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. ERIC KULLMAN</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>58224</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 2, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <results_first_submitted>October 4, 2017</results_first_submitted>
  <results_first_submitted_qc>October 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2018</results_first_posted>
  <last_update_submitted>October 4, 2017</last_update_submitted>
  <last_update_submitted_qc>October 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARIETEX Composite Ventral Patch</keyword>
  <keyword>PCO VP OR PCOVP</keyword>
  <keyword>Primary ventral hernia repair</keyword>
  <keyword>Panacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PARIETEX™ Composite Ventral Patch</title>
          <description>PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning
PARIETEX™ Composite Ventral Patch for ventral hernia repair</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Consented and enrolled population 126 (100.0) Completed Study 100 (79.4) Discontinued early 26 (20.6)</population>
      <group_list>
        <group group_id="B1">
          <title>PARIETEX™ Composite Ventral Patch</title>
          <description>PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning
PARIETEX™ Composite Ventral Patch for ventral hernia repair</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.2" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Hernia Recurrence Rate at 24 Month Follow‐up.</title>
        <description>The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography.</description>
        <time_frame>24 month follow‐up</time_frame>
        <population>101 patients returned for 24 month Follow-Up Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>PARIETEX™ Composite Ventral Patch</title>
            <description>PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning
PARIETEX™ Composite Ventral Patch for ventral hernia repair</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Hernia Recurrence Rate at 24 Month Follow‐up.</title>
          <description>The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography.</description>
          <population>101 patients returned for 24 month Follow-Up Visit.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence Rate at 1, 6 and 12 Month Follow‐up</title>
        <description>The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit.</description>
        <time_frame>1, 6 and 12 month follow‐up.</time_frame>
        <population>The number analyzed reflects the number of participants who returned for 1 month, 6 month and 12 month follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Undergoing Primary Ventral Hernia Repair</title>
            <description>Patients undergoing primary ventral hernia repair using PARIETEX™ Composite Ventral Patch (PCO-VP)</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence Rate at 1, 6 and 12 Month Follow‐up</title>
          <description>The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit.</description>
          <population>The number analyzed reflects the number of participants who returned for 1 month, 6 month and 12 month follow-up visits.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 month follow-up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pain Score at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months</title>
        <description>Pain evaluation as determined by a 10-point pain intensity numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain). Scores reported at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months</description>
        <time_frame>Various (Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months)</time_frame>
        <population>The number analyzed includes participants who completed the NRS pain scale</population>
        <group_list>
          <group group_id="O1">
            <title>Hernia Patients Receiving Surgery</title>
            <description>Number of participants receiving surgery with PARIETEX™ Composite Ventral Patch for primary ventral hernia repair</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months</title>
          <description>Pain evaluation as determined by a 10-point pain intensity numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain). Scores reported at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months &amp; 24 Months</description>
          <population>The number analyzed includes participants who completed the NRS pain scale</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="125"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of Risk Factors at Baseline</title>
        <description>Summary of Risk factors at Baseline. Risk factors include: Smoker, Obesity, Diabetes T1 &amp; T2, Cancer, Cardiovascular disease, Hypertension, COPD, Chronic desease requiring analgesic or corticoid consumption</description>
        <time_frame>Baseline</time_frame>
        <population>Number of patients with risk factors at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Hernia Patients Enrolled at Baseline</title>
            <description>All patients enrolled at Baseline and assessed for risk factors</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Risk Factors at Baseline</title>
          <description>Summary of Risk factors at Baseline. Risk factors include: Smoker, Obesity, Diabetes T1 &amp; T2, Cancer, Cardiovascular disease, Hypertension, COPD, Chronic desease requiring analgesic or corticoid consumption</description>
          <population>Number of patients with risk factors at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity (BMI&gt;=30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Disease-Analgesic Consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Disease-Corticoid consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mesh Handling Ease of Use During Surgery</title>
        <description>Ease of use (mesh handling and comfort of use). Surgeons were asked if they were satisfied or completely satisfied, unsatisfied or completely dissatisfied</description>
        <time_frame>Per- operative</time_frame>
        <population>Overal patients treated with PCO Ventral patch</population>
        <group_list>
          <group group_id="O1">
            <title>Ease of Use</title>
            <description>Ease of use (mesh handling and manipulability, comfort of use …)</description>
          </group>
        </group_list>
        <measure>
          <title>Mesh Handling Ease of Use During Surgery</title>
          <description>Ease of use (mesh handling and comfort of use). Surgeons were asked if they were satisfied or completely satisfied, unsatisfied or completely dissatisfied</description>
          <population>Overal patients treated with PCO Ventral patch</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Completely satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unsatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Completely dissatisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Other Relevant Data: Operative Time</title>
        <description>Operative time during surgery for all patient receiving PCO ventral patch</description>
        <time_frame>Per- operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Operative Time</title>
            <description>Operative time during surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Other Relevant Data: Operative Time</title>
          <description>Operative time during surgery for all patient receiving PCO ventral patch</description>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Other Relevant Data: Time of Mesh Positioning</title>
        <description>The time of the mesh positioning during surgery</description>
        <time_frame>Per- operative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Time Mesh Positioning</title>
            <description>Time positioning of the mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Other Relevant Data: Time of Mesh Positioning</title>
          <description>The time of the mesh positioning during surgery</description>
          <units>min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PARIETEX™ Composite Ventral Patch</title>
          <description>PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra‐peritoneal positioning
PARIETEX™ Composite Ventral Patch for ventral hernia repair</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michelle DiSalvo</name_or_title>
      <organization>Medtronic</organization>
      <phone>774 284 6089</phone>
      <email>michelle.v.disalvo@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

